CN109761778A - A kind of method of synthesizing optical active alpha-hydroxypropanamide derivative - Google Patents

A kind of method of synthesizing optical active alpha-hydroxypropanamide derivative Download PDF

Info

Publication number
CN109761778A
CN109761778A CN201811502645.XA CN201811502645A CN109761778A CN 109761778 A CN109761778 A CN 109761778A CN 201811502645 A CN201811502645 A CN 201811502645A CN 109761778 A CN109761778 A CN 109761778A
Authority
CN
China
Prior art keywords
methyl
hydroxy
bromo
cyano
propionamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811502645.XA
Other languages
Chinese (zh)
Inventor
方瑜
杜玉民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shijiazhuang Wisdom Medical Technology Co Ltd
Original Assignee
Shijiazhuang Wisdom Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Wisdom Medical Technology Co Ltd filed Critical Shijiazhuang Wisdom Medical Technology Co Ltd
Priority to CN201811502645.XA priority Critical patent/CN109761778A/en
Publication of CN109761778A publication Critical patent/CN109761778A/en
Pending legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a kind of methods of synthesizing optical active alpha-hydroxypropanamide derivative, belong to organic synthesis field.By using proline as chiral auxiliary; nucleophilic substitution occurs through acylation, bromination, de- chiral auxiliary and 4- cyano -3- 5-trifluoromethylaniline with methacrylic chloride, obtains the bromo- 2- hydroxy-2-methyl-N- of 3- [(4- cyano -3- trifluoromethyl) phenyl] propionamide.Nucleophilic substitution occurs with 4-hydroxybenzonitrile again, optically active compound 3- (4- cyano-benzene oxygen)-N- [4- cyano -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide is made.Ammonolysis occurs using the bromo- 2- hydroxy-2-methyl propionic acid of optically active 3- and 4- nitro-3-trifluoromethylaniline, nucleophilic substitution occurs with to acetaminophenol, optically active compound 3- (4- acetoxyl group phenoxy group)-N- [4- nitro -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide is made.The present invention is a kind of to efficiently synthesize optical activity alpha-hydroxypropanamide derivative method.

Description

A kind of method of synthesizing optical active alpha-hydroxypropanamide derivative
Technical field
The present invention relates to a kind of methods of synthesizing optical active alpha-hydroxypropanamide derivative, belong to organic synthesis field.
Background technique
(2S) -3- (4- cyano-benzene oxygen)-N- [4- cyano -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide (Enobosarm, S-V) is a kind of selective non-steroidal androgen receptor regulator by the research and development of GTx company, the U.S., is used for The diseases such as muscular atrophy and osteoporosis are treated, are currently carried out for amyotrophic clinical examination caused by kinds cancer It tests.In completed 8 I phases and II clinical trial phase the results show that Enobosarm can be obviously improved the thin body of cancer patient Weight and muscle strength and function.In the amyotrophic III phase clinic examination for the treatment of Patients with Non-small-cell Lung that in July, 2011 starts Test, investigated Enobosarm whether be able to ascend patient body function and maintenance or increase Lean mass, data is In arrangement, if Enobosarm can reach expected test objective, it will become first and be used to prevent and treat muscle loss Or the drug of atrophy.
(2S) -3- (4- acetylamino phenoxy group)-N- [4- nitro -3- trifluoromethyl] -2- hydroxy-2-methyl propionyl Amine (Andarine, S- VII) is equally a kind of selective androgen receptor regulator by the research and development of GTx company, the U.S., is used for Treat the diseases such as muscular atrophy, osteoporosis and benign prostatauxe.The structure of Andarine and Enobosarm extremely phase Seemingly, to its synthetic method research can thus class formation new drug exploitation provide technical support.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, The present invention is that operation is easy and efficient for one kind, the Lactoyl amine derivative synthetic method of high quality.
The technical solution used in the present invention is: a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative:
By nucleophilic substitution occurring with methacrylic chloride, obtains 1- (2- methyl 1. using proline as chiral auxiliary Acryloyl group) nafoxidine -2- carboxylic acid;2. 1- (2- methylacryloyl) nafoxidine -2- carboxylic acid and N- bromo succinyl are sub- Bromination reaction occurs for amine (NBS), obtains bromomethyl -3- methyl nafoxidine simultaneously [2,1-c] [Isosorbide-5-Nitrae] oxazines-Isosorbide-5-Nitrae-diketone;3. passing through Hydrobromic acid hydrolysis, sloughs chiral auxiliary, obtains the bromo- 2- hydroxy-2-methyl propionic acid of optically active 3-.
Optically active bromo- 2- hydroxy-2-methyl propionic acid of 3- and thionyl chloride effect generate acyl chlorides, then with 4- cyano- Nucleophilic substitution occurs for 3- 5-trifluoromethylaniline, obtains the bromo- 2- hydroxy-2-methyl-N- of 3- [(4- cyano -3- trifluoromethyl) benzene Base] propionamide;The bromo- 2- hydroxy-2-methyl-N- of 3- [(4- cyano -3- trifluoromethyl) phenyl] propionamide under potassium carbonate catalysis Nucleophilic substitution occurs with 4-hydroxybenzonitrile, optically active compound 3- (4- cyano-benzene oxygen)-N- [4- cyano -3- is made Trifluoromethyl] -2- hydroxy-2-methyl propionamide.
Optically active bromo- 2- hydroxy-2-methyl propionic acid of 3- and thionyl chloride effect generate acyl chlorides, then with 4- nitro- Nucleophilic substitution occurs for 3- 5-trifluoromethylaniline, obtains the bromo- 2- hydroxy-2-methyl-N- of 3- [(4- nitro -3- trifluoromethyl) benzene Base] propionamide;The bromo- 2- hydroxy-2-methyl-N- of 3- [(4- nitro -3- trifluoromethyl) benzene under the catalysis of benzyl tributyl ammonium chloride Base] propionamide with to acetaminophenol occur nucleophilic substitution, be made optically active compound 3- (4- acetyloxy phenyl oxygen Base)-N- [4- nitro -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide.The present invention is that one kind efficiently synthesizes optics work The method of property Lactoyl amine derivative.Synthetic route is as follows:
(2S) -3- (4- cyano-benzene oxygen)-N- [4- cyano -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide The synthesis of (Enobosarm, S-V)
(2R) -3- (4- cyano-benzene oxygen)-N- [4- cyano -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide (R-V) synthesis
(2S) -3- (4- acetylamino phenoxy group)-N- [4- nitro -3- trifluoromethyl] -2- hydroxy-2-methyl propionyl The synthesis of amine (Andarine, S- VII)
(2R) -3- (4- acetylamino phenoxy group)-N- [4- nitro -3- trifluoromethyl] -2- hydroxy-2-methyl propionyl The synthesis of amine (R- VII)
Specific embodiment
Embodiment
The synthesis of (2R) -1- (2- methylacryloyl) nafoxidine -2- carboxylic acid (R- I)
D-PROLINE (20.80g, 180.8mmol) is dissolved in 2mol/L sodium hydroxide solution (90mL), acetone is added (90mL), ice bath are cooled to 5~10 DEG C, under stirring, and methacrylic chloride (28.20g, 271.1mmol) and tetrahydrofuran is added dropwise The mixed solution of (30mL), while pH11~12 of 2mol/L sodium hydroxide solution (113mL) control reaction solution are added dropwise.It drips Finish, 3h is stirred at room temperature.Remove organic solvent under reduced pressure, Liquid Residue is adjusted to pH 5 with 6mol/L sulfuric acid solution, is extracted with ethyl acetate. Liquid Residue continues to be acidified to pH 2 with 6mol/L sulfuric acid solution, is extracted with ethyl acetate (40mL × 5), merges organic layer, with nothing Aqueous sodium persulfate dries, filters, and is concentrated under reduced pressure, obtains I 27.74g of white solid R-, yield 83.8%, mp.102~103 DEG C.(3R, The synthesis of 8R)-bromomethyl -3- methyl nafoxidine simultaneously [2,1-c] [1,4] oxazines -1,4- diketone (II a)
Compound R-I (27.70g, 151.2mmol) is dissolved in N, in N- methylacetamide (120mL).Nitrogen protection condition Under, the mixing that N- bromo-succinimide (NBS) (53.82g, 302.4mmol) and N, N- methylacetamide (200mL) is added dropwise is molten Liquid.It is added dropwise, 5h is stirred at room temperature, reaction solution is poured into distilled water (600mL), solid is precipitated, and stirs 0.5h, filters, obtains II a 24.16g of white solid, yield 60.9%, mp.151~153 DEG C are obtained with re-crystallizing in ethyl acetate to crude product.
(R)-(+) synthesis of the bromo- 2- hydroxy-2-methyl propionic acid (R- III) of -3-
Compound ii a (21.00g, 80.1mmol) is dissolved in 24% hydrobromic acid solution (168mL), reflux is warming up to, is protected Temperature reaction 5h.End of reaction is cooled to room temperature, and is added distilled water (210mL), (40mL × 3) are extracted with ethyl acetate, are associated with Machine layer extracts (40mL × 3) with saturated sodium bicarbonate solution, and combining water layer is acidified to pH 2 with concentrated hydrochloric acid, is extracted with ethyl acetate It takes (30mL × 4), merges organic layer, anhydrous sodium sulfate dries, filters, and evaporating solvent under reduced pressure obtains crude product, is tied again with toluene Crystalline substance filters, dry, obtains III 13.41g of white, needle-shaped crystals R-, yield 91.3%, mp.107~109 DEG C.
(R)-(-) the bromo- 2- hydroxy-2-methyl-N- of -3- [(4- cyano -3- trifluoromethyl) phenyl] propionamide (R- IV) Synthesis
By compound R-III (6.00g, 32.9mmol), 4- cyano -3- 5-trifluoromethylaniline (6.79g, 36.5mmol) and N, N- methylacetamide (42mL) are added in reaction flask, and ice bath is cooled to -15 DEG C, be added dropwise thionyl chloride (4.60g, 39.0mmol), -10 DEG C~-15 DEG C of reaction temperature are controlled.It is added dropwise, after insulated and stirred 0.5h, rises to 40 DEG C of reaction 3h.It will Reaction solution is poured slowly into cold saturated sodium bicarbonate solution (120mL), is extracted with ethyl acetate (30mL × 3), is merged organic Phase, saturated sodium chloride solution washing, filters, evaporating solvent under reduced pressure obtains crude product, with the mixing of petroleum ether and methyl tertiary butyl ether(MTBE) Solution recrystallization, decolorizing with activated carbon obtain IV 9.30g of white solid R-, yield 80.4%, mp.133~135 DEG C.
(2S) -3- (4- cyano-benzene oxygen)-N- [4- cyano -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide (S-V) synthesis
Compound R-IV (30.0g, 85mmol) and 4-hydroxybenzonitrile (12.2g, 102mmol) are dissolved in isopropanol In (300mL), it is added Anhydrous potassium carbonate (35.4g, 256mmol), under the conditions of nitrogen protection, back flow reaction 0.5h.Evaporated under reduced pressure Solvent, residue are dissolved in distilled water (300mL), are extracted with ethyl acetate (150mL × 2), merge organic phase, with 10% hydrogen-oxygen Change sodium solution washing (100mL × 3), washed (200mL) with saturated sodium chloride solution, anhydrous sodium sulfate is dry, filters, filtrate rotation It is dry, crude product is obtained, with re crystallization from toluene, active carbon decoloring obtains white solid S-V25.1g, yield 75.5%, mp.90~91 DEG C.
The synthesis of (2S) -1- (2- methylacryloyl) nafoxidine -2- carboxylic acid (S- I)
L-PROLINE (10.40g, 90.4mmol) is dissolved in 2mol/L sodium hydroxide solution (45mL), acetone is added (45mL), ice bath is cooling, stirring.At 5~10 DEG C, methacrylic chloride (14.10g, 135.5mmol) and tetrahydrofuran is added dropwise The mixed solution of (15mL), while 2mol/L sodium hydroxide solution (59mL) control reaction solution pH11~12 are added dropwise.It is added dropwise, 3h is stirred at room temperature, removes organic solvent under reduced pressure, Liquid Residue is acidified to pH 5 with 6mol/L sulfuric acid solution, is extracted with ethyl acetate. Liquid Residue continues to be acidified to pH 2 with 6mol/L sulfuric acid solution, is extracted with ethyl acetate (20mL × 5), merges organic layer, with nothing Aqueous sodium persulfate dries, filters, and is concentrated to dryness, and obtains I 13.18g of white solid S-, yield 79.6%, mp.101~103 DEG C. The synthesis of (3S, 8S)-bromomethyl -3- methyl nafoxidine simultaneously [2,1-c] [1,4] oxazines -1,4- diketone (II b)
Compound S- I (13.00g, 71.0mmol) is dissolved in n,N-dimethylacetamide (56mL).Nitrogen protection condition Under, the mixed solution of NBS (25.26g, 141.9mmol) and n,N-dimethylacetamide (95mL) is added dropwise.It is added dropwise, room temperature 5h is stirred, reaction solution is poured into distilled water (300mL), solid is precipitated, and stirs 0.5h, filters, obtains crude product, use ethyl acetate Recrystallization, obtains II b 9.93g of white solid, yield 53.4%, mp.155~156 DEG C.
(S)-(+) synthesis of the bromo- 2- hydroxy-2-methyl propionic acid (S- III) of -3-
Compound ii b (9.90g, 37.8mmol) is dissolved in 24% hydrobromic acid solution (80mL), reflux is warming up to, is kept the temperature React 5h.End of reaction is cooled to room temperature, and is added distilled water (100mL), is extracted with ethyl acetate (25mL × 3), is merged organic Layer.Organic layer extracts (25mL × 3) with saturated sodium bicarbonate solution, combining water layer.Water layer enriching hydrochloric acid is acidified to pH 2, uses second Acetoacetic ester extracts (20mL × 4), merges organic layer, adds anhydrous sodium sulfate dry, filters, filtrate is spin-dried for, obtains crude product, use toluene Recrystallization, it is dry, obtain III 6.12g of white, needle-shaped crystals S-, yield 88.5%, mp.108~109 DEG C.
(S)-(-) the bromo- 2- hydroxy-2-methyl-N- of -3- [(4- cyano -3- trifluoromethyl) phenyl] propionamide (S- IV) Synthesis
By compound S- III (30.0g, 164mmol), 4- cyano -3- 5-trifluoromethylaniline (33.9g, 182mmol) and N, N- methylacetamide (210mL) is added in reaction flask, and ice bath is cooled to -15 DEG C, is added dropwise thionyl chloride (23.0g, 195mmol), Reaction temperature is controlled at -10 DEG C~-15 DEG C.It finishes, insulated and stirred 0.5h, rises to 40 DEG C of reaction 2h.Reaction solution is poured slowly into It in cold saturated sodium bicarbonate solution (60mL), is extracted with ethyl acetate (200mL × 3), merges organic phase, saturated sodium-chloride is molten Liquid washing, anhydrous sodium sulfate are dried, filtered, are concentrated to dryness, and crude product are obtained, with the mixing of petroleum ether and methyl tertiary butyl ether(MTBE) Solution recrystallization, decolorizing with activated carbon obtain IV 42.3g of white solid S-, yield 73.1%, mp.106~108 DEG C.
(2R) -3- (4- cyano-benzene oxygen)-N- [4- cyano -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide (R-V) synthesis
Compound S- IV (30.0g, 85mmol) and 4-hydroxybenzonitrile (12.2g, 102mmol) are dissolved in isopropanol In (300mL), it is added Anhydrous potassium carbonate (35.4g, 256mmol), under the conditions of nitrogen protection, back flow reaction 0.5h.Evaporated under reduced pressure Solvent, residue are dissolved in distilled water (300mL), are extracted with ethyl acetate (150mL × 2), merge organic phase, with 10% hydrogen-oxygen Change sodium solution washing (100mL × 3), wash (200mL) with saturated sodium chloride solution, anhydrous sodium sulfate dries, filters, and depressurizes dense It is reduced to dry, obtains crude product, with re crystallization from toluene, active carbon decoloring obtains white solid R-V23.2g, yield 69.7%, mp.91~92 ℃。
(R)-(-) the bromo- 2- hydroxy-2-methyl-N- of -3- [(4- nitro -3- trifluoromethyl) phenyl] propionamide (R- VI) Synthesis
By compound R-III (30.0g, 164mmol), 4- nitro-3-trifluoromethylaniline (26.0g, 126mmol) and N, N- methylacetamide (200mL) is added in reaction flask, and ice bath is cooled to -15 DEG C, is added dropwise thionyl chloride (22.3g, 189mmol), Temperature is controlled at -10 DEG C~-15 DEG C.It finishes, insulated and stirred 0.5h, rises to 40 DEG C of reaction 8h.Reaction solution is poured slowly into cold It in saturated sodium bicarbonate solution (600mL), is extracted with ethyl acetate (150mL × 3), merges organic phase, saturated sodium chloride solution Washing, anhydrous sodium sulfate are dried, filtered, are concentrated to dryness, be purified by silica gel column chromatography, and obtain VI 34.8g of yellow solid R-, are received Rate 57.2%, mp.98~99 DEG C.
2.3.2 (2S) -3- (4- acetylamino phenoxy group)-N- [4- nitro -3- trifluoromethyl] -2- hydroxyl -2- first The synthesis of base propionamide (S- VII)
Isopropanol is dissolved in by compound R-VI (20.0g, 54mmol) and to acetaminophenol (12.2g, 81mmol) In (300mL), Anhydrous potassium carbonate (14.9g, 108mmol) and 10% benzyl tributyl ammonium chloride (2.0g), nitrogen protection is added Under the conditions of, back flow reaction 4h.Evaporated under reduced pressure solvent, residue are dissolved in distilled water (200mL), and (100mL is extracted with ethyl acetate × 2), merge organic phase, (1,0mL × 3) are washed with 10% sodium hydroxide solution, with anhydrous saturated sodium chloride solution (150mL) Washing, anhydrous sodium sulfate are dried, filtered, are concentrated to dryness, and obtain crude product, and with re crystallization from toluene, it is solid to obtain yellow for active carbon decoloring VII 18.5g of body S-, yield 77.8%, mp.70~72 DEG C.
(S)-(-) the bromo- 2- hydroxy-2-methyl-N- of -3- [(4- nitro -3- trifluoromethyl) phenyl] propionamide (S- VI) Synthesis
By compound S- III (30.0g, 164mmol), 4- nitro-3-trifluoromethylaniline (26.0g, 126mmol) and N, N- methylacetamide (200mL) is added in reaction flask, and ice bath is cooled to -15 DEG C, is added dropwise thionyl chloride (22.3g, 189mmol), Temperature is controlled at -10 DEG C~-15 DEG C.It finishes, insulated and stirred 0.5h, rises to 40 DEG C of reaction 8h.Reaction solution is poured slowly into cold It in saturated sodium bicarbonate solution (600mL), is extracted with ethyl acetate (150mL × 3), merges organic phase, saturated sodium chloride solution Washing, anhydrous sodium sulfate dry, filter, and evaporating solvent under reduced pressure is purified by silica gel column chromatography, and obtain VI 34.6g of yellow solid S-, receive Rate 56.9%, mp.100~102 DEG C.
(2R) -3- (4- acetylamino phenoxy group)-N- [(4- nitro -3- trifluoromethyl) phenyl] -2- hydroxy-2-methyl third The synthesis of amide (R- VII)
Isopropanol is dissolved in by compound S- VI (10.0g, 27mmol) and to acetaminophenol (6.1g, 41mmol) In (150mL), Anhydrous potassium carbonate (7.4g, 54mmol) and 10% benzyl tributyl ammonium chloride (1.0g), nitrogen protection item is added Under part, back flow reaction 4h.Evaporated under reduced pressure solvent, residue are dissolved in distilled water (150mL), be extracted with ethyl acetate (100mL × 2), merge organic phase, wash (100mL × 3) with 10% sodium hydroxide solution, wash (100mL), nothing with saturated sodium chloride solution Aqueous sodium persulfate dries, filters, and is concentrated to dryness, and obtains crude product, and with re crystallization from toluene, active carbon decoloring obtains yellow solid R- VII 9.4g, yield 79.3%, mp.71~73 DEG C.

Claims (10)

1. a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, which comprises the following steps:
(1) synthesis of the bromo- 2- hydroxy-2-methyl propionic acid of (R) -3- and the bromo- 2- hydroxy-2-methyl propionic acid of (S) -3-
1. under alkaline condition, nucleophilic substitution occurs for D-PROLINE and methacrylic chloride in organic solvent, (2R)-is obtained 1- (2- methylacryloyl) nafoxidine -2- carboxylic acid (R- I);Parent occurs for L-PROLINE and methacrylic chloride under similarity condition Core substitution reaction obtains (2S) -1- (2- methylacryloyl) nafoxidine -2- carboxylic acid (R- I).
Bromination reaction occurs for (2. 2R) -1- (2- methylacryloyl) nafoxidine -2- carboxylic acid and bromide reagent, obtain (3R, 8R)-bromomethyl -3- methyl nafoxidine simultaneously [2,1-c] [Isosorbide-5-Nitrae] oxazines-II a of Isosorbide-5-Nitrae-diketone;
Bromination reaction occurs for (2S) -1- (2- methylacryloyl) nafoxidine -2- carboxylic acid and bromide reagent, obtains (3S, 8S) - Bromomethyl -3- methyl nafoxidine simultaneously [2,1-c] [Isosorbide-5-Nitrae] oxazines-II b of Isosorbide-5-Nitrae-diketone.
3. simultaneously [2,1-c] [Isosorbide-5-Nitrae] oxazines-Isosorbide-5-Nitrae-diketone through sour water solution, obtains (3R, 8R)-bromomethyl -3- methyl nafoxidine (R) the bromo- 2- hydroxy-2-methyl propionic acid (R- III) of -3-;
Simultaneously [2,1-c] [Isosorbide-5-Nitrae] oxazines-Isosorbide-5-Nitrae-diketone obtains (S) -3- through sour water solution to (3S, 8S)-bromomethyl -3- methyl nafoxidine Bromo- 2- hydroxy-2-methyl propionic acid (S- III).
4. the bromo- 2- hydroxy-2-methyl propionic acid of (R) -3- and chlorination reagent act on, then exist with 4- cyano -3- 5-trifluoromethylaniline Nucleophilic substitution occurs under the conditions of alkalinity and certain temperature, obtains the bromo- 2- hydroxy-2-methyl-N- of (R) -3- [(4- cyano -3- three Methyl fluoride) phenyl] propionamide;
(S) the bromo- 2- hydroxy-2-methyl propionic acid of -3- and chlorination reagent act on, then with 4- cyano -3- 5-trifluoromethylaniline in alkali Nucleophilic substitution occurs under the conditions of property and certain temperature, obtains the bromo- 2- hydroxy-2-methyl-N- of (S) -3- [(4- cyano -3- trifluoro Methyl) phenyl] propionamide.
(2) (2S) -3- (4- cyano-benzene oxygen)-N- [4- cyano -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide and The synthesis of (2R) -3- (4- cyano-benzene oxygen)-N- [4- cyano -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide
Under base catalysis, in aprotic polar organic solvent, the bromo- 2- hydroxy-2-methyl-N- of (R) -3- [(4- cyano -3- trifluoro Methyl) phenyl] nucleophilic substitution occurs for propionamide and 4-hydroxybenzonitrile, compound (2S) -3- (4- cyano-benzene oxygen)-is made N- [4- cyano -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide (S-V);
Under base catalysis, in aprotic polar organic solvent, the bromo- 2- hydroxy-2-methyl-N- of (S) -3- [(4- cyano -3- trifluoro Methyl) phenyl] nucleophilic substitution occurs for propionamide and 4-hydroxybenzonitrile, compound (2R) -3- (4- cyano-benzene oxygen)-is made N- [4- cyano -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide (R-V).
(3) (2S) -3- (4- acetoxyl group phenoxy group)-N- [4- nitro -3- trifluoromethyl] -2- hydroxy-2-methyl propionyl Amine and (2S) -3- (4- acetoxyl group phenoxy group)-N- [4- nitro -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide Synthesis
1. the bromo- 2- hydroxy-2-methyl propionic acid of (R) -3- is reacted with chlorination reagent, then sent out with 4- nitro-3-trifluoromethylaniline Raw nucleophilic substitution, obtains the bromo- 2- hydroxy-2-methyl-N- of (R) -3- [(4- nitro -3- trifluoromethyl) phenyl] propionamide (R- Ⅵ);
(S) the bromo- 2- hydroxy-2-methyl propionic acid of -3- is reacted with chlorination reagent, is then occurred with 4- nitro-3-trifluoromethylaniline Nucleophilic substitution obtains the bromo- 2- hydroxy-2-methyl-N- of (S) -3- [(4- nitro -3- trifluoromethyl) phenyl] propionamide (S- Ⅵ)。
2. under phase transfer catalyst effect, the bromo- 2- hydroxy-2-methyl-N- of (R) -3- [(4- nitro -3- trifluoromethyl) phenyl] With to acetaminophenol nucleophilic substitution occurs for propionamide, and compound (2S) -3- (4- acetoxyl group phenoxy group)-N- is made [4- nitro -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide (S- VII);
Under phase transfer catalyst effect, the bromo- 2- hydroxy-2-methyl-N- of (S) -3- [(4- nitro -3- trifluoromethyl) phenyl] third With to acetaminophenol nucleophilic substitution occurs for amide, and compound (2R) -3- (4- acetoxyl group phenoxy group)-N- is made [4- nitro -3- trifluoromethyl] -2- hydroxy-2-methyl propionamide (R- VII).
The present invention is a kind of to efficiently synthesize optical activity alpha-hydroxypropanamide derivative method.
2. a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, feature described in (1) exist according to claim 1 In the alkaline condition is sodium hydroxide, potassium hydroxide, ammonium hydroxide, one of lithium hydroxide.
3. a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, feature described in (1) exist according to claim 1 In organic solvent is one of ketone and tetrahydrofuran mixed solvent, such as acetone, butanone, 2 pentanone of low molecular weight.
4. a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, feature described in (1) exist according to claim 1 In bromide reagent is the carbon tetrachloride solution of N- bromo-succinimide (NBS) or bromine.
5. a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, feature described in (1) exist according to claim 1 In acid used is sulfuric acid, hydrochloric acid, hydrobromic acid, preferably 24% hydrobromic acid.
6. a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, feature described in (1) exist according to claim 1 In chlorination reagent used is thionyl chloride, phosphorus trichloride and phosphorus pentachloride, preferably thionyl chloride.
7. a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, feature described in (1) exist according to claim 1 In alkali used is sodium carbonate, potassium carbonate, triethylamine, diisopropylethylamine, N-methylcyclohexylamine, preferably triethylamine.Reaction temperature Degree is preferably room temperature.
8. a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, feature described in (2) exist according to claim 1 In alkali used is sodium carbonate, potassium carbonate, triethylamine, diisopropylethylamine, N-methylcyclohexylamine, preferably potassium carbonate.
9. a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, feature described in (2) exist according to claim 1 In aprotic polar organic solvent used is n,N-Dimethylformamide or n,N-dimethylacetamide.
10. a kind of method of synthesizing optical active alpha-hydroxypropanamide derivative, feature described in (3) according to claim 1 It is, phase transfer catalyst is benzyl tributyl ammonium chloride, benzyl tributyl ammonium bromide, benzyltriethylammoinium chloride, benzyl three Ethyl phosphonium bromide ammonium etc..It is preferred that benzyl tributyl ammonium chloride.
CN201811502645.XA 2018-12-10 2018-12-10 A kind of method of synthesizing optical active alpha-hydroxypropanamide derivative Pending CN109761778A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811502645.XA CN109761778A (en) 2018-12-10 2018-12-10 A kind of method of synthesizing optical active alpha-hydroxypropanamide derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811502645.XA CN109761778A (en) 2018-12-10 2018-12-10 A kind of method of synthesizing optical active alpha-hydroxypropanamide derivative

Publications (1)

Publication Number Publication Date
CN109761778A true CN109761778A (en) 2019-05-17

Family

ID=66451357

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811502645.XA Pending CN109761778A (en) 2018-12-10 2018-12-10 A kind of method of synthesizing optical active alpha-hydroxypropanamide derivative

Country Status (1)

Country Link
CN (1) CN109761778A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110981794A (en) * 2019-12-19 2020-04-10 宁波耆健医药科技有限公司 Synthetic method of nicotinate
CN111018740A (en) * 2019-12-20 2020-04-17 阿里生物新材料(常州)有限公司 Synthesis method of 4-bromo-2-cyano-5-fluorobenzoic acid methyl ester
CN111138353A (en) * 2019-12-19 2020-05-12 宁波耆健医药科技有限公司 Nicotinate hydrate and preparation method thereof
CN111646922A (en) * 2020-07-21 2020-09-11 阿里生物新材料(常州)有限公司 Synthetic method of 2- (4-bromo-2-cyano-6-fluorophenyl) acetic acid
CN112250599A (en) * 2020-11-24 2021-01-22 阿里生物新材料(常州)有限公司 Synthesis method of 4-bromo-2-cyano-3-fluorobenzoic acid methyl ester

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1826313A (en) * 2003-01-13 2006-08-30 Gtx公司 Large-scale synthesis of selective androgen receptor modulators
CN101516840A (en) * 2006-07-12 2009-08-26 田纳西大学研究基金会 Substituted acylanilides and methods of use thereof
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
CN103251579A (en) * 2006-08-24 2013-08-21 田纳西大学研究基金会 Substituted acylanilides and methods of use thereof
CN106999453A (en) * 2014-10-16 2017-08-01 Gtx公司 The method that urological disorders are treated using SARM
CN107709290A (en) * 2015-04-21 2018-02-16 Gtx公司 Selective androgen receptor degradation agent (SARD) part and its application method
CN108143728A (en) * 2012-07-13 2018-06-12 Gtx公司 Purposes of the selective androgen receptor modulators in breast cancer is treated
US20190111010A1 (en) * 2012-07-13 2019-04-18 Gtx, Inc. Method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
CN1826313A (en) * 2003-01-13 2006-08-30 Gtx公司 Large-scale synthesis of selective androgen receptor modulators
CN101516840A (en) * 2006-07-12 2009-08-26 田纳西大学研究基金会 Substituted acylanilides and methods of use thereof
CN103251579A (en) * 2006-08-24 2013-08-21 田纳西大学研究基金会 Substituted acylanilides and methods of use thereof
CN108143728A (en) * 2012-07-13 2018-06-12 Gtx公司 Purposes of the selective androgen receptor modulators in breast cancer is treated
US20190111010A1 (en) * 2012-07-13 2019-04-18 Gtx, Inc. Method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)
CN106999453A (en) * 2014-10-16 2017-08-01 Gtx公司 The method that urological disorders are treated using SARM
CN107709290A (en) * 2015-04-21 2018-02-16 Gtx公司 Selective androgen receptor degradation agent (SARD) part and its application method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARHEFKA, CRAIG A.等: "《Homology Modeling Using Multiple Molecular Dynamics Simulations and Docking Studies of the Human Androgen Receptor Ligand Binding Domain Bound to Testosterone and Nonsteroidal Ligands》", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110981794A (en) * 2019-12-19 2020-04-10 宁波耆健医药科技有限公司 Synthetic method of nicotinate
CN111138353A (en) * 2019-12-19 2020-05-12 宁波耆健医药科技有限公司 Nicotinate hydrate and preparation method thereof
CN111018740A (en) * 2019-12-20 2020-04-17 阿里生物新材料(常州)有限公司 Synthesis method of 4-bromo-2-cyano-5-fluorobenzoic acid methyl ester
CN111018740B (en) * 2019-12-20 2022-04-05 阿里生物新材料(常州)有限公司 Synthesis method of 4-bromo-2-cyano-5-fluorobenzoic acid methyl ester
CN111646922A (en) * 2020-07-21 2020-09-11 阿里生物新材料(常州)有限公司 Synthetic method of 2- (4-bromo-2-cyano-6-fluorophenyl) acetic acid
CN111646922B (en) * 2020-07-21 2022-03-11 阿里生物新材料(常州)有限公司 Synthetic method of 2- (4-bromo-2-cyano-6-fluorophenyl) acetic acid
CN112250599A (en) * 2020-11-24 2021-01-22 阿里生物新材料(常州)有限公司 Synthesis method of 4-bromo-2-cyano-3-fluorobenzoic acid methyl ester
CN112250599B (en) * 2020-11-24 2022-03-11 阿里生物新材料(常州)有限公司 Synthesis method of 4-bromo-2-cyano-3-fluorobenzoic acid methyl ester

Similar Documents

Publication Publication Date Title
CN109761778A (en) A kind of method of synthesizing optical active alpha-hydroxypropanamide derivative
CN101426783B (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006046499A1 (en) Indoline compound and process for producing the same
CN105601524B (en) The preparation of LCZ696 key intermediates
JP4921646B2 (en) 1- (3-Benzyloxypropyl) -5- (2-substituted propyl) indoline derivatives and methods of use thereof
CN101432275A (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN102827042B (en) Chiral synthesis method of florfenicol
WO1992019604A1 (en) Novel isoxazole derivative and salt thereof
CN104829672B (en) A kind of synthetic method of pharmaceutical intermediate
CN103086938A (en) Ezetimibe synthesis method
CN110183357A (en) It is a kind of to be used to prepare preparation method of the Sha Ku than bent intermediate
WO2023143158A1 (en) Phenol derivative, crystal form thereof, and preparation method therefor
CN103936638A (en) Synthetic method of florfenicol
CN101462988B (en) Technique for synthesizing bicalutamide
CN106977543A (en) The preparation technology of improved Suo Feibuwei intermediates
CN102477008B (en) Method for synthesizing ezetimibe
CN105523999A (en) Dabigatran etexilate intermediate synthesis method
CN104418839A (en) Synthetic method of dabigatran etexilate
WO2012062109A1 (en) Methods for preparation of pharmaceutical intermediates of aliskiren
WO2021100730A1 (en) Method for producing pyrrolidine compound
CN105541742B (en) A kind of preparation method of ezetimibe intermediate
CN106496089B (en) A method of preparing Oxiracetam
CN108440395A (en) A kind of preparation method of milrinone impurity
JP2007217440A (en) Purification method for optically active alpha-trifluoromethyl lactate
CN108059608A (en) A kind of preparation method of Ezetimibe

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190517